Induced Pluripotent Stem Cells Market Size (2024 - 2029)

The induced pluripotent stem cells market is projected to experience significant growth over the forecast period, driven by increased research and development activities in stem cell therapies and a rising adoption of personalized medicine. The market's expansion is further supported by the growing use of iPSC-derived models for drug screening and understanding viral infections, which gained prominence during the COVID-19 pandemic. Additionally, strategic business initiatives such as collaborations and agreements are expected to enhance the utilization of iPSCs in clinical research, contributing to market growth. However, challenges such as a lack of awareness and high treatment costs may impede the market's progress.

Market Size of Induced Pluripotent Stem Cells Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Induced Pluripotent Stem Cells Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 1.35 Billion
Market Size (2029) USD 2.18 Billion
CAGR (2024 - 2029) 10.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Induced Pluripotent Stem Cells Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Induced Pluripotent Stem Cells (iPSCs) Market Analysis

The Induced Pluripotent Stem Cells Market size is estimated at USD 1.35 billion in 2024, and is expected to reach USD 2.18 billion by 2029, growing at a CAGR of 10.10% during the forecast period (2024-2029).

The COVID-19 pandemic has imposed a great burden on the healthcare sector as most chronic therapies were postponed and all outpatient treatments were delayed or restricted during the COVID-19 pandemic to lower the risk of viral transmission. Several studies on cell therapies have demonstrated their potential to modulate the immune response by controlling cell function and downregulating inflammatory cytokines, which aids in lowering COVID-19 patients' mortality and morbidity rates. For instance, according to an article published in Molecular Biomedical, in February 2022, stem cells have demonstrated promising results in clinical studies for treating COVID-19 disease by altering the immune system. In addition, as per an article published in Frontiers in Cell and Development Biology, in September 2021, it has been observed that human induced pluripotent stem cell (iPSC)-derived cellular and organoid models provide useful platforms for in vitro simulation of viral life cycles and drug screening to prevent coronavirus reemergence. Also, these iPSC-derived models can recapitulate the functions and physiology of various human cell types and assemble complex microenvironments, hence increasing the study efficiency of viral infection mechanisms, and mimicking the actual host-virus interaction. Thus, with the increased use of stem cells, the market has witnessed significant growth during the pandemic.

Factors such as the increase in R&D activities in stem cell therapies and the surge in the adoption of personalized medicines are expected to boost market growth over the forecast period.

The rise in the prevalence of personalized medicines for various disease treatments is expected to increase the company's focus to accelerate the adoption of induced pluripotent stem cells in developing therapies. For instance, as per an article published in the Journal of Personalized Medicine, in August 2022, it has been observed that iPSCs generated from individuals with a variety of monogenic and polygenic disorders, provide a valuable resource for developing individualized models of psychiatric diseases that help researchers to better understand the underlying molecular and cellular pathways. The same source also stated that the researchers discovered biomarkers, including synaptic connectivity and morphology changes as well as specific gene expression, for the bupropion response in lymphoblastoid cell lines (LCLs) from major depressive disorder (MDD) that had been reprogrammed to iPSC and differentiated into cortical neurons. Thus, the utilization of LCLs in obtaining several biomarkers is expected to promote personalized treatment options for patients suffering from MDD, thereby bolstering market growth.

Moreover, the growing company's focus on adopting various business strategies such as agreements, collaborations, and other initiatives is expected to increase the utilization and production of iPSCs in clinical research, thereby contributing to market growth. For instance, in January 2022, Century Therapeutics signed a research collaboration and license agreement with Bristol Myers Squibb to develop and commercialize up to four induced pluripotent stem cell-derived, engineered natural killer cell ('iNK') and/or T cell ('iT') programs for hematologic malignancies and solid tumors. Also, in November 2021, Ncardia, a human-induced pluripotent stem cell company, signed a USD 60 million funding deal with Kiniciti to expand discovery and commercial production services for stem cells.

Therefore, owing to the aforementioned factors, such as increasing company focus on utilizing induced pluripotent stem cells in the R&D of drugs and other therapies as well as growing demand for personalized medicines, the studied market is anticipated to grow over the forecast period. However, the lack of awareness regarding stem cell therapies and the high cost of treatment is likely to hinder the growth of the induced pluripotent stem cells market over the forecast period.

Induced Pluripotent Stem Cells (iPSCs) Industry Segmentation

As per the scope of the report, induced pluripotent stem cells are a type of stem cell that could be generated from a somatic cell. Induced pluripotent stem cells (iPSCS) are created by causing terminally differentiated somatic cells to revert to pluripotency by chemical or genetic reprogramming. The Induced Pluripotent Stem Cells Market is Segmented by Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, and Others), Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, and Cell Therapy, and Disease Modelling), End User (Research Institutions and Other End Users) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.

By Derived Cell Type
Hepatocytes
Fibroblasts
Keratinocytes
Neurons
Others
By Application
Drug Development
Regenerative Medicine
Toxicity Testing
Tissue Engineering
Cell Therapy
Disease Modeling
By End User
Research Institutions
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Induced Pluripotent Stem Cells Market Size Summary

The induced pluripotent stem cells (iPSC) market is poised for significant growth, driven by advancements in regenerative medicine and the increasing adoption of personalized medicine. iPSCs, which are reprogrammed from somatic cells, offer unique advantages such as self-renewal and the ability to differentiate into various cell lineages, making them a valuable tool in regenerative therapies. The market is experiencing a surge in research and development activities, with companies focusing on utilizing iPSCs for drug development and therapeutic applications. The COVID-19 pandemic has further accelerated the use of iPSCs, as they have shown potential in modulating immune responses and serving as models for viral studies. This has led to increased interest and investment in iPSC technologies, contributing to the market's expansion.

The market is characterized by a competitive landscape with key players engaging in strategic collaborations, mergers, and product launches to strengthen their market position. North America is expected to hold a significant share due to its advanced technological adoption and substantial research funding. Government initiatives and funding are also playing a crucial role in promoting iPSC research and development, enhancing the market's growth prospects. Despite the promising growth trajectory, challenges such as high treatment costs and limited awareness about stem cell therapies may hinder market expansion. Nonetheless, the ongoing advancements and increasing focus on personalized medicine are anticipated to drive the market forward over the forecast period.

Explore More

Induced Pluripotent Stem Cells Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increase in Research and Development Activities in Stem Cells Therapies

      2. 1.2.2 Surge in Adoption of Personalized Medicine

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness Regarding Stem Cell Therapies and High Cost of Treatment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Derived Cell Type

      1. 2.1.1 Hepatocytes

      2. 2.1.2 Fibroblasts

      3. 2.1.3 Keratinocytes

      4. 2.1.4 Neurons

      5. 2.1.5 Others

    2. 2.2 By Application

      1. 2.2.1 Drug Development

      2. 2.2.2 Regenerative Medicine

      3. 2.2.3 Toxicity Testing

      4. 2.2.4 Tissue Engineering

      5. 2.2.5 Cell Therapy

      6. 2.2.6 Disease Modeling

    3. 2.3 By End User

      1. 2.3.1 Research Institutions

      2. 2.3.2 Other End Users

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Induced Pluripotent Stem Cells Market Size FAQs

The Induced Pluripotent Stem Cells Market size is expected to reach USD 1.35 billion in 2024 and grow at a CAGR of 10.10% to reach USD 2.18 billion by 2029.

In 2024, the Induced Pluripotent Stem Cells Market size is expected to reach USD 1.35 billion.

Induced Pluripotent Stem Cells Production Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)